NeuroOne Medical Technologies Corporation will participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference virtually on March 17, 2026. Company President and CEO Dave Rosa and CFO Ron McClurg will host one-on-one meetings with institutional investors during the event. Rosa is scheduled to deliver a company presentation at 1:20 p.m. Eastern Time that will provide commercialization updates and pipeline milestones for the OneRF platform for treatment of the brain, pain, and advanced drug delivery.
The presentation represents a significant opportunity for NeuroOne to communicate its progress to the investment community during a period of expansion for its FDA-cleared technologies. The company's electrode technology platform includes four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System for brain, and OneRF Trigeminal Nerve Ablation System. These minimally invasive solutions offer combination diagnostic and therapeutic functions that could potentially reduce hospitalizations and surgical procedures while lowering costs and improving patient outcomes.
For business and technology leaders monitoring the medical technology sector, NeuroOne's participation in this conference signals continued momentum in the neurological disorder treatment market. The company's focus on transforming surgical diagnosis and treatment of neurological disorders through advanced electrode technology represents a growing segment within healthcare technology. The OneRF platform's expansion into pain management and advanced drug delivery suggests broader applications beyond initial neurological indications.
The virtual format of the Oppenheimer 36th Annual Healthcare MedTech & Services Conference allows for broader accessibility to NeuroOne's updates. Interested parties can access the presentation through the conference webcast available at https://wsw.com/webcast/oppenheimer36/nmtc/ and find additional conference information at https://www.oppenheimer.com/conferences/36th-annual-healthcare-medtech-services-conference. These platforms provide investors and industry observers with direct access to management's strategic vision and operational progress.
NeuroOne's research and development activities extend beyond its current product offerings to include drug delivery and spinal cord stimulation programs. This pipeline development work positions the company at the intersection of medical device technology and pharmaceutical delivery systems, creating potential synergies in neurological treatment approaches. The company's technologies are restricted to sale by or on the order of a physician in accordance with federal regulations, emphasizing their specialized medical application.
The implications of NeuroOne's conference presentation extend beyond investor relations to the broader healthcare technology landscape. As neurological disorders affect millions globally, advancements in minimally invasive treatment options could significantly impact healthcare delivery models. The company's approach to combining diagnostic and therapeutic functions within single platforms addresses growing demands for more efficient and effective neurological care. For business leaders evaluating investment opportunities in healthcare technology, NeuroOne's progress represents both technological innovation and potential market expansion in specialized medical device sectors.
